As a leading company in the field of OA and Pain, IBSA gladly announces its participation in the EFIC Congress with a Satellite Symposium focusing on the use of glycosaminoglycans (GAGs) in the management of OA, namely:
- pharmaceutical grade chondroitin sulfate (CS)
- highly purified hyaluronic acid for i.a. injection (HA)
from their structure to the clinical benefits. New data about the “hybrid cooperative complexes” of HA will be also presented.
See the full programme here.
All people interested in knowing more about IBSA and its pipeline of products (Condrosulf/chondroitin sulphate; Sinovial/i.a. HA; Flector/diclofenac epolamine; Akis-Dicloin/subcutaneous diclofenac) are also invited to visit us in the exhibition hall.